FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W830749931> ?p ?o ?g. }

• W830749931 endingPage "2057" @default.
• W830749931 startingPage "2057" @default.
• W830749931 abstract "Abstract Background Bronchiolitis Obliterans Syndrome (BOS) is a late-onset non-infectious pulmonary complication of HSCT, resulting in obstructive lung disease. BOS is thought to be a manifestation of chronic graft versus host disease (cGVHD). BOS can also occur after lung transplantation, where it is believed to represent chronic rejection of the lung allograft. In both conditions, the mainstay of therapy includes augmentation of systemic immunosuppression. However, this approach has limited efficacy and is associated with deleterious consequences including an increased risk of infection and decreased graft versus tumor/leukemia effects. We investigated whether targeted, local delivery of inhaled cyclosporine could improve or stabilize lung function in BOS patients. Methods HSCT recipients with BOS, ages 10-80, were eligible if they met the following inclusion criteria: FEV1&lt;75% predicted, FEV1 decline &gt;10% compared to pre-transplant FEV1, no evidence of pulmonary infection as a causative etiology, and one of the following: FEV1/FVC ratio &lt;70%, air-trapping seen on CT scan or RV ≥120%, or evidence of cGVHD affecting at least one other organ system. Lung transplant recipients with BOS were also eligible. Subjects were characterized as having progressive or stable disease at study entry based on their FEV1 values in the preceding 3-18 weeks. Progressive disease was defined as a ≥10% decline in FEV1, and stable disease as an increase in FEV &lt;5% or a decrease &lt;10%. Subjects received cyclosporine inhalation solution (CIS) 150 mg via nebulizer 3 times weekly for 6 weeks before dose escalation to 300mg three times weekly. The primary endpoint was change in FEV1 at study completion (average of week 18 and 19 values) compared to study baseline. Pharmacokinetic sampling and lung deposition studies were performed on all subjects. Lung deposition studies were performed using SPECT/CT imaging after inhalation of CIS mixed with technetium- 99m sulfur colloid. Bronchoalveolar lavage fluid and peripheral blood samples were collected at study baseline, week 9 and week 18, and were analyzed for cytokine markers and lymphocyte phenotype. Six minute walk tests (6MWT) and quality of life testing was also performed. Results Eleven subjects (nine evaluable) have been enrolled (median age: 45 years; range: 14-73). Nine subjects had HSCT-associated BOS, and 2 had lung-transplant-associated BOS. Patients were transplanted for various underlying conditions (MDS, aplastic anemia, DLBCL, MM, ALL, Gata-2 deficiency, alpha-1 anti-trypsin deficiency, and idiopathic pulmonary fibrosis). HSCT recipients received both reduced intensity (n=4) and myeloablative (n=5) conditioning, with allografts from HLA matched relatives (n=5) or unrelated donors (n=4). The median time from BOS diagnosis to study enrollment was 9 months (range: 2-37 mos). The median FEV1 at study entry was 1.11 liters (range: 0.5-2.11), with 4 subjects having progressive disease and 7 stable disease. Adverse events associated with CIS occurred in 9/10 patients and included cough, bronchospasm, and dyspnea. Most adverse events were grade 2 (range:1-3) and occurred only during the inhalation. Three subjects went off-study (patient choice) prior to completion of the 18 weeks due to adverse events and were considered non-responders. Four of the 8 (50%) HSCT- associated BOS subjects had a response, including 3 patients with progressive disease and 1 with stable disease at study entry. Among these responders, the improvements in absolute FEV1 from baseline were 19.5%, 15%, 12.7%, and 3.4% respectively (figure). Among the responding patients, 2 were also able to decrease their systemic steroid administration by 50% and 43%. An improvement in 6MWT was noted in 1/4 responders. Four responders have enrolled onto an extension protocol. The median peak systemic absorption of cyclosporine was 99 mcg/L (Range: 32-263) 20 minutes post-CIS inhalation. Lung deposition studies showed the total deposited dose averaged 12% (range: 4-20 %) of the inhaled dose. Conclusions Inhaled cyclosporine can be delivered safely and can stabilize or improve lung function in HSCT recipients with severe BOS, allowing systemic immunosuppression to be reduced. Use of local, targeted therapy with CIS resulted in minimal systemic absorption compared to typical oral administration, and achieved high drug levels in the lung tissue as demonstrated by the lung deposition results. Disclosures: No relevant conflicts of interest to declare." @default.
• W830749931 created "2016-06-24" @default.
• W830749931 creator A5002718422 @default.
• W830749931 creator A5007255619 @default.
• W830749931 creator A5008093274 @default.
• W830749931 creator A5017127832 @default.
• W830749931 creator A5021627028 @default.
• W830749931 creator A5025157938 @default.
• W830749931 creator A5026071592 @default.
• W830749931 creator A5029041351 @default.
• W830749931 creator A5034482742 @default.
• W830749931 creator A5049066393 @default.
• W830749931 creator A5051959420 @default.
• W830749931 creator A5062647579 @default.
• W830749931 creator A5074515375 @default.
• W830749931 creator A5076074380 @default.
• W830749931 creator A5077898822 @default.
• W830749931 creator A5081724953 @default.
• W830749931 creator A5086275373 @default.
• W830749931 creator A5087705062 @default.
• W830749931 date "2013-11-15" @default.
• W830749931 modified "2023-10-16" @default.
• W830749931 title "Inhaled Cyclosporine For The Treatment Of Bronchiolitis Obliterans Following Hematopoietic Stem Cell Transplantation (HSCT) Or Lung Transplantation" @default.
• W830749931 doi "https://doi.org/10.1182/blood.v122.21.2057.2057" @default.
• W830749931 hasPublicationYear "2013" @default.
• W830749931 type Work @default.
• W830749931 sameAs 830749931 @default.
• W830749931 citedByCount "3" @default.
• W830749931 countsByYear W8307499312015 @default.
• W830749931 countsByYear W8307499312019 @default.
• W830749931 countsByYear W8307499312023 @default.
• W830749931 crossrefType "journal-article" @default.
• W830749931 hasAuthorship W830749931A5002718422 @default.
• W830749931 hasAuthorship W830749931A5007255619 @default.
• W830749931 hasAuthorship W830749931A5008093274 @default.
• W830749931 hasAuthorship W830749931A5017127832 @default.
• W830749931 hasAuthorship W830749931A5021627028 @default.
• W830749931 hasAuthorship W830749931A5025157938 @default.
• W830749931 hasAuthorship W830749931A5026071592 @default.
• W830749931 hasAuthorship W830749931A5029041351 @default.
• W830749931 hasAuthorship W830749931A5034482742 @default.
• W830749931 hasAuthorship W830749931A5049066393 @default.
• W830749931 hasAuthorship W830749931A5051959420 @default.
• W830749931 hasAuthorship W830749931A5062647579 @default.
• W830749931 hasAuthorship W830749931A5074515375 @default.
• W830749931 hasAuthorship W830749931A5076074380 @default.
• W830749931 hasAuthorship W830749931A5077898822 @default.
• W830749931 hasAuthorship W830749931A5081724953 @default.
• W830749931 hasAuthorship W830749931A5086275373 @default.
• W830749931 hasAuthorship W830749931A5087705062 @default.
• W830749931 hasConcept C126322002 @default.
• W830749931 hasConcept C141071460 @default.
• W830749931 hasConcept C203014093 @default.
• W830749931 hasConcept C2776739411 @default.
• W830749931 hasConcept C2777223847 @default.
• W830749931 hasConcept C2777408962 @default.
• W830749931 hasConcept C2777714996 @default.
• W830749931 hasConcept C2779972918 @default.
• W830749931 hasConcept C2780252810 @default.
• W830749931 hasConcept C2781448352 @default.
• W830749931 hasConcept C2911091166 @default.
• W830749931 hasConcept C71924100 @default.
• W830749931 hasConcept C75603125 @default.
• W830749931 hasConcept C90924648 @default.
• W830749931 hasConceptScore W830749931C126322002 @default.
• W830749931 hasConceptScore W830749931C141071460 @default.
• W830749931 hasConceptScore W830749931C203014093 @default.
• W830749931 hasConceptScore W830749931C2776739411 @default.
• W830749931 hasConceptScore W830749931C2777223847 @default.
• W830749931 hasConceptScore W830749931C2777408962 @default.
• W830749931 hasConceptScore W830749931C2777714996 @default.
• W830749931 hasConceptScore W830749931C2779972918 @default.
• W830749931 hasConceptScore W830749931C2780252810 @default.
• W830749931 hasConceptScore W830749931C2781448352 @default.
• W830749931 hasConceptScore W830749931C2911091166 @default.
• W830749931 hasConceptScore W830749931C71924100 @default.
• W830749931 hasConceptScore W830749931C75603125 @default.
• W830749931 hasConceptScore W830749931C90924648 @default.
• W830749931 hasIssue "21" @default.
• W830749931 hasLocation W8307499311 @default.
• W830749931 hasOpenAccess W830749931 @default.
• W830749931 hasPrimaryLocation W8307499311 @default.
• W830749931 hasRelatedWork W1895478142 @default.
• W830749931 hasRelatedWork W1896091522 @default.
• W830749931 hasRelatedWork W2072014979 @default.
• W830749931 hasRelatedWork W2085369110 @default.
• W830749931 hasRelatedWork W2169692571 @default.
• W830749931 hasRelatedWork W2344986991 @default.
• W830749931 hasRelatedWork W2433042874 @default.
• W830749931 hasRelatedWork W2557030025 @default.
• W830749931 hasRelatedWork W2992364290 @default.
• W830749931 hasRelatedWork W4213107070 @default.
• W830749931 hasVolume "122" @default.
• W830749931 isParatext "false" @default.
• W830749931 isRetracted "false" @default.
• W830749931 magId "830749931" @default.
• W830749931 workType "article" @default.